ASBRON Drug Patent Profile
✉ Email this page to a colleague
When do Asbron patents expire, and what generic alternatives are available?
Asbron is a drug marketed by Novartis and is included in one NDA.
The generic ingredient in ASBRON is theophylline sodium glycinate. There is one drug master file entry for this compound. Additional details are available on the theophylline sodium glycinate profile page.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for ASBRON?
- What are the global sales for ASBRON?
- What is Average Wholesale Price for ASBRON?
Summary for ASBRON
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 20 |
| DailyMed Link: | ASBRON at DailyMed |
US Patents and Regulatory Information for ASBRON
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Novartis | ASBRON | theophylline sodium glycinate | TABLET;ORAL | 085148-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
